Completed Access to Information Requests

Follow:

  • RSS
  • Cite
About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA). For additional information, please see the “About Access to Information Requests” webpage.

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Current Search

Report Type

Organization

Disposition

Year

Month

Found 440 record(s)

Req # A-2022-001602

Adverse Drug Reactions (ADRs). Report numbers: E2B_05999062, E2B_05970123, E2B_05998743, E2B_05984698, 001020501, E2B_06008302, E2B_05984446, E2B_06001031, E2B_06004067.

Organization: Health Canada

284 page(s)
July 2023

Req # A-2022-001604

Adverse Drug Reactions (ADRs). Report numbers: 001026185, 001022431, 001021230, E2B_05970570.

Organization: Health Canada

57 page(s)
July 2023

Req # A-2022-001614

Adverse Drug Reactions (ADRs). Report numbers: E2B_02641517, E2B_02675533, E2B_02791931, 000915904, E2B_02821447, E2B_02864513, 000922266, 000927627, 000934959, 000936174.

Organization: Health Canada

95 page(s)
July 2023

Req # A-2022-001619

Adverse Drug Reaction (ADR). Report number: 001026724.

Organization: Health Canada

8 page(s)
July 2023

Req # A-2022-001624

Adverse Drug Reactions (ADRs). Report numbers: E2B_05127159, E2B_05189982, E2B_05043162, E2B_05096839, E2B_02413518, 000927984, E2B_03466359, E2B_02747441, E2B_05785361, 001010550.

Organization: Health Canada

922 page(s)
July 2023

Req # A-2022-001657

Adverse Drug Reactions (ADRs). Report numbers: 001013659, E2B_02989790, E2B_05372962, E2B_04181634, E2B_04181139, E2B_03794891, E2B_03293332, E2B_05740582, E2B_05799925, E2B_05738680.

Organization: Health Canada

516 page(s)
July 2023

Req # A-2022-001686

Adverse Drug Reactions (ADRs). Report numbers: 001021717, E2B_05824479, E2B_05789236, E2B_03383022, E2B_02732043, E2B_01465889, E2B_05752679, E2B_05468464, E2B_02249603, E2B_05874043.

Organization: Health Canada

1187 page(s)
July 2023

Req # A-2023-000004

Adverse Drug Reaction (ADR) for PANTOPRAZOLE SODIUM. Report number: E2B_06055213. ADR for ADDERALL XR. Report number: 001024861. ADRs for MESALAZINE. Report numbers: E2B_06032558, E2B_06033711, E2B_06117931, E2B_06029464, 001025065, 001024500, 001024467, 001026009.

Organization: Health Canada

148 page(s)
July 2023

Req # A-2023-000005

Adverse Drug Reactions (ADRs) for C1 ESTERASE INHIBITOR (HUMAN). Report numbers: E2B_06059052, E2B_06083180, E2B_06058994, E2B_06059067, E2B_06057820, E2B_06059038, E2B_06059475, E2B_06076092, E2B_06066944, E2B_06029786.

Organization: Health Canada

152 page(s)
July 2023

Req # A-2023-000010

Adverse Drug Reaction (ADR). Report number: E2B_03816205.

Organization: Health Canada

7 page(s)
July 2023
Date modified: